Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Gabriela Hobbs, MD; Rami Komrokji, MD; and Douglas A. Tremblay, MD; discuss the management of low-risk polycythemia vera (PV) based on the latest data.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Analyze recent clinical trial data and guideline updates related to treating PV and ET
• Implement evidence-based treatment strategies for both newly diagnosed and previously treated patients with PV and ET
• Identify the best practices for providing supportive care and monitoring symptoms in patients with PV and ET

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Incyte Corporation.

Chair:

Gabriela Hobbs, MD

Associate Professor
Harvard Medical School
Clinical Director, Leukemia Service
Massachusetts General Hospital
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Bristol Myers Squibb, Cogent, GSK, Incyte, Merck, PharmaEssentia, Sobi; Grant/Research Funding: Incyte; Ownership interests in publicly traded companies: Regeneron

Faculty:

Rami Komrokji, MD

Section Head, Leukemia and MDS
Vice Chair, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Bristol Myers Squibb, DSI, Geron, GSK, Novartis, PharmaEssentia, Rigel, Servier, Sobi, Stemline, Sumitomo Pharma, Takeda; Speakers Bureau: DSI, PharmaEssentia, Rigel, Servier, Sobi; Grant/ Research Funding: Bristol Myers Squibb

Douglas A. Tremblay, MD

Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Advisor, Consultant, Speaker, Fee-for-Service Recipient: AbbVie, Cogent Biosciences, Geron, GSK, Ipsen, PharmaEssentia, Sobi; Grant/Research Funding: Blueprint, Cogent Biosciences, Geron, Oryzon, Sobi, Sumitomo

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on high-risk polycythemia vera and essential thrombocythemia, go to https://www.gotoper.com/courses/cases-and-conversations-adopting-new-treatment-strategies-in-polycythemia-vera-and-essential-thrombocythemia-fvrl.

Release Date

July 23, 2026

Expiration Date

July 23, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.